23 Nov 08 Long-Term TITAN Study Evaluates PREZISTA(R)/ritonavir Vs. Lopinavir/ritonavir As Part Of HIV Combination Therapy In Treatment-Experienced Adults
Tibotec recently announced long-term study results from a phase 3 clinical trial, which compared PREZISTA(R) (darunavir)/ritonavir to lopinavir/ritonavir, as part of HIV combination therapy, in lopinavir/r-naive, treatment-experienced HIV-1 infected adults. A 96-week resistance analysis from the study, known as TITAN, was presented in an oral presentation at the Ninth International Congress on Drug Therapy in HIV Infection (HIV9) in Glasgow, UK on November 13, 2008.
(more…)
Tags: Adults, Clinical Trial, Darunavir, Glasgow Uk, Hiv, Hiv Combination Therapy, Hiv Infection, Lopinavir, Ninth International Congress, Oral Presentation, Phase 3, Prezista, Resistance Analysis, Ritonavir, Titan
17 Nov 08 Case Of Patient "Cured" Of HIV Baffles Doctors
Doctors and experts are baffled by the case of a 42-year old male American patient living in Berlin whose 10-year long HIV infection appears to have been “cured” by a bone marrow transplant given to treat his acute myeloid leukemia.
(more…)
Tags: Acute Myeloid Leukemia, American Patient, Baffles, Bone Marrow, Doctors, Hiv, Hiv Infection, Leukemia, Living In Berlin
09 Nov 08 Researchers Examining Protein Communication To Prevent HIV
Researchers at Carnegie Mellon University Language Technologies Institute are using statistical computer methods to identify which proteins could prevent HIV infection by listening to signals from a drug instead of the virus, the Pittsburgh Tribune-Review reports.
(more…)
Tags: Carnegie Mellon University, Communication, Computer Methods, Hiv, Hiv Infection, Hiv Researchers, Language Technologies Institute, Pittsburgh Tribune Review, Protein, Proteins, Signals, University Language, Virus
09 Nov 08 HIV Replication Inhibited By Herpes Drug, But With A Price
The anti-herpes drug acyclovir can also directly slow down HIV infection by targeting the reverse transcriptase (RT) enzyme, researchers report in this week’s JBC. This beneficial effect does pose a risk though, as HIV-infected cells treated with acyclovir promote the emergence of multi-drug resistant HIV variants. HIV and herpes (HSV) are two of the most common sexually transmitted diseases worldwide, and individuals frequently become co-infected with both.
(more…)
Tags: Acyclovir, Beneficial Effect, Cells, Common Sexually Transmitted Diseases, Drug Resistant Hiv, Emergence, Enzyme Researchers, Herpes, Herpes Hsv, Hiv, Hiv Infection, Hiv Replication, Hiv Variants, Jbc, Reverse Transcriptase, Risk
05 Nov 08 Experimental HIV vaccine may have increased infection risk: study (AFP)
AFP - Trials of a once-promising experimental HIV vaccine were cut short in 2007 because the drug may have increased the likelihood of HIV infection rather than preventing it, according to a new study.
(more…)
Tags: Hiv, Hiv Infection, Hiv Risk, Hiv Vaccine, Infection Risk, Likelihood, Risk Study
05 Nov 08 How HIV Vaccine Might Have Increased Odds Of Infection
In September 2007, a phase II HIV-1 vaccine trial was abruptly halted when researchers found that the vaccine may have promoted, rather than prevented, HIV infection. A new study by a team of researchers at the Montpellier Institute of Molecular Genetics in France shows how the vaccine could have enhanced HIV infection. The study, lead by Matthieu Perreau, will be published online on November 3 of the Journal of Experimental Medicine.
(more…)
Tags: France, Hiv, Hiv Infection, Hiv Vaccine, Journal Of Experimental Medicine, Lead, Medicine, Molecular Genetics, Montpellier, Odds, Phase Ii, Vaccine Trial
04 Nov 08 Study Sheds Light On The Mechanisms Of Increased Risk Of HIV Infection In The Step HIV Vaccine Trial
A study published today online in The Journal of Experimental Medicine sheds light on the potential mechanisms responsible for the increased incidence of HIV infection that was observed in the failed STEP HIV vaccine trial in 2007. Through the development of an experimental in vitro model, the study shows that the immune complexes formed by antibodies and the adenovirus vector (the Trojan horse for the delivery of the vaccine) induce a strong activation signal of key cells, i.e.
(more…)
Tags: Antibodies, Cells, Hiv, Hiv Infection, Hiv Vaccine Trial, Immune Complexes, Journal Of Experimental Medicine, Mechanisms, Medicine, Risk Of Hiv, Sheds, Trojan Horse, Vector, Vitro
16 Oct 08 AIDS rife in Indonesian prisons: official (AFP)
AFP - The HIV/AIDS infection rate is exploding in Indonesian prisons because intravenous drug users are being kept in the same overcrowded cells as other inmates, officials said Thursday.
(more…)
Tags: Afp, Aids, Aids Infection, Cells, Hiv, Hiv Aids, Hiv Infection, Inmates, Intravenous Drug Users, Prisons
14 Oct 08 Iran reports 30% rise in HIV infection on 2007 (AFP)
AFP - The number of people in Iran who have been infected with the AIDS virus has reached 18,320 people, a 30 percent increase on the 2007 figure, health ministry statistics showed on Tuesday.
(more…)
Tags: Afp, Aids, Aids Virus, Health Ministry, Hiv, Hiv Infection, Iran, Ministry Statistics, People
06 Oct 08 Progenics Announces Progress And Presentations In HIV Therapy Program - Enrollment For PRO 140 Phase 2 Clinical Studies Completed
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the completion of enrollment in two, phase 2 clinical studies of PRO 140, an investigational drug that is being developed for treatment of human immunodeficiency virus (HIV) infection. The phase 2 studies are separately evaluating intravenous and subcutaneous forms of PRO 140.
(more…)
Tags: Hiv, Hiv Infection, Hiv Therapy, Human Immunodeficiency Virus, Human Virus, Immunodeficiency Virus Hiv, Investigational Drug, Nasdaq, Pgnx, Phase 2, Presentations, Progenics Pharmaceuticals Inc, Program Enrollment, Virus Infection
03 Oct 08 What HIV Needs: Identification Of Human Factors May Yield Novel Therapeutic Targets For HIV
The Salk Institute for Biological Studies and Burnham Institute for Medical Research today announced 295 host cell factors that are involved in human immunodeficiency virus (HIV) infection. The study, published in the Oct. 3 issue of Cell, could lead to the development of a new class of HIV therapeutics aimed at disrupting the human-HIV interactions that lead to viral infection. The research, a collaborative effort between the laboratories of Sumit K. Chanda, Ph.
(more…)
Tags: Burnham Institute For Medical Research, Chanda, Collaborative Effort, Hiv, Hiv Infection, Host Cell, Human Factors, Human Immunodeficiency Virus, Human Virus, Immunodeficiency Virus Hiv, Lead, Novel, Salk Institute For Biological Studies, Sumit, Therapeutic Targets, Viral Infection, Virus Infection
25 Sep 08 HIV on rise among self-injecting drug users: study (Reuters)
Reuters - The rate of HIV infection among people who inject themselves with drugs appears to be rising, according to a study published on Wednesday.
(more…)
Tags: Drug Users, Drugs, Hiv, Hiv Infection, Rate People, Reuters, Self Study
24 Sep 08 HIV on rise among self-injecting drug users: study
LONDON (Reuters) - The rate of HIV infection among people who inject themselves with drugs appears to be rising, according to a study published on Wednesday.
Tags: Drug Users, Drugs, Hiv, Hiv Infection, London Reuters, Rate People, Self Study
23 Sep 08 HIV on rise among self-injecting drug users: study
LONDON (Reuters) - The rate of HIV infection among people who inject themselves with drugs appears to be rising, according to a study published on Wednesday.
Tags: Drug Users, Drugs, Hiv, Hiv Infection, London Reuters, Rate People, Self Study
